Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure

Larsson, 2007, Diabetes mellitus and risk of breast cancer: a meta-analysis, Int J Cancer, 121, 856, 10.1002/ijc.22717 Friberg, 2007, Diabetes mellitus and risk of endometrial cancer: a meta-analysis, Diabetologia, 50, 1365, 10.1007/s00125-007-0681-5 Bonovas, 2004, Diabetes mellitus and risk of prostate cancer: a meta analysis, Diabetologia, 47, 1071, 10.1007/s00125-004-1415-6 Kasper, 2006, A meta-analysis of diabetes mellitus and the risk of prostate cancer, Cancer Epidemiol Biomarkers Prev, 15, 2056, 10.1158/1055-9965.EPI-06-0410 El-Serag, 2006, The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence, Clin Gastroenterol Hepatol, 4, 369, 10.1016/j.cgh.2005.12.007 Wang, 2012, Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis, Diabetes Metab Res Rev, 28, 109, 10.1002/dmrr.1291 Huxley, 2005, Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies, Br J Cancer, 92, 2076, 10.1038/sj.bjc.6602619 Ben, 2011, Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies, Eur J Cancer, 47, 1928, 10.1016/j.ejca.2011.03.003 Larsson, 2006, Diabetes mellitus and risk of bladder cancer: a meta-analysis, Diabetologia, 49, 2819, 10.1007/s00125-006-0468-0 Larsson, 2005, Diabetes mellitus and risk of colorectal cancer: a meta-analysis, J Natl Cancer Inst, 97, 1679, 10.1093/jnci/dji375 Deng, 2012, Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis, Dig Dis Sci, 57, 1576, 10.1007/s10620-012-2055-1 Erbach, 2012, Diabetes and the risk for colorectal cancer, J Diabetes Complications, 26, 50, 10.1016/j.jdiacomp.2011.11.003 Sun, 2012, Diabetes mellitus is an independent risk factor for colorectal cancer, Dig Dis Sci, 57, 1586, 10.1007/s10620-012-2059-x Larsson, 2011, Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies, Diabetologia, 54, 1013, 10.1007/s00125-011-2051-6 Mitri, 2008, Diabetes and risk of non-Hodgkins lymphoma: a meta-analysis of observational studies, Diabetes Care, 31, 2391, 10.2337/dc08-1034 Vigneri, 2009, Diabetes and cancer, Endoc Relat Cancer, 16, 1103, 10.1677/ERC-09-0087 Giovannucci, 2010, Diabetes and cancer: a consensus report, Diabetes Care, 33, 1674, 10.2337/dc10-0666 Nicolucci, 2010, Epidemiological aspects of neoplasms in diabetes, Acta Diabetol, 47, 87, 10.1007/s00592-010-0187-3 Onitilo, 2012, Diabetes and cancer II: role of diabetes drugs and influence of shared risk factors, Cancer Causes Control, 23, 991, 10.1007/s10552-012-9971-4 Dejgaard, 2009, No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis, Diabetologia, 52, 2507, 10.1007/s00125-009-1568-4 Home, 2009, Combined randomised controlled trial experience of malignancies in studies using insulin glargine, Diabetologia, 52, 2499, 10.1007/s00125-009-1530-5 Pollak, 2010, Insulin analogues and cancer risk: cause for concern or cause celebre?, Int J Clin Pract, 64, 628, 10.1111/j.1742-1241.2010.02354.x Chowdhury, 2010, Diabetes and cancer, QJM, 103, 905, 10.1093/qjmed/hcq149 Currie, 2009, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes, Diabetologia, 52, 1766, 10.1007/s00125-009-1440-6 Bowker, 2006, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin, Diabetes Care, 29, 254, 10.2337/diacare.29.02.06.dc05-1558 Currie, 2012, Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival, Diabetes Care, 35, 299, 10.2337/dc11-1313 Suissa, 2012, Metformin and the risk of cancer, Diabetes Care, 35, 2665, 10.2337/dc12-0788 Govindarajan, 2007, Thiazolidinediones and the risk of lung, prostate and colon cancer in patients with diabetes, J Clin Oncol, 25, 1476, 10.1200/JCO.2006.07.2777 Ramos-Nino, 2007, Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System, BMC Med, 5, 17, 10.1186/1741-7015-5-17 Monami, 2008, Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials, Diabetes Care, 31, 1455, 10.2337/dc07-2308 Monami, 2009, Sulphonylureas and cancer: a case control study, Acta Diabetol, 46, 279, 10.1007/s00592-008-0083-2 Tseng, 2011, Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan, Diabetologia, 54, 2009, 10.1007/s00125-011-2171-z Knudsen, 2010, Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation, Endocrinology, 51, 1473, 10.1210/en.2009-1272 Elashoff, 2011, Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1 based therapies, Gastroenterology, 141, 150, 10.1053/j.gastro.2011.02.018 Brubaker, 2010, Minireview: update on incretin biology: focus on glucagon-like peptide-1, Endocrinology, 151, 1984, 10.1210/en.2010-0115 Butler, 2010, Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?, Diabetologia, 53, 1, 10.1007/s00125-009-1591-5 Drucker, 2010, Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits, Diabetes Care, 33, 428, 10.2337/dc09-1499 Monami, 2011, Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials, Curr Med Res Opin, 27, 57, 10.1185/03007995.2011.602964 Cai, 2012, The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials, J Clin Pharm Ther, 37, 386, 10.1111/j.1365-2710.2011.01323.x Bhartia, 2011, SGLT-2 inhibitors in development for type 2 diabetes treatment, Rev Diabet Stud, 8, 348, 10.1900/RDS.2011.8.348 Fonseca, 2008, Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy, Diabetes Care, 31, 1479, 10.2337/dc08-0283 Ferrara, 2011, Cohort study of pioglitazone and cancer incidence in patients with diabetes, Diabetes Care, 34, 923, 10.2337/dc10-1067 Libby, 2009, New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes, Diabetes Care, 32, 1620, 10.2337/dc08-2175 Koro, 2007, Cancer risks in thiazolidinedione users compared to other anti diabetic agents, Pharmacoepidemiol Drug Saf, 16, 485, 10.1002/pds.1352 Jiralerspong, 2010, Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer, J Clin Oncol, 27, 3297, 10.1200/JCO.2009.19.6410 Landman, 2010, Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16, Diabetes Care, 33, 322, 10.2337/dc09-1380 Yang, 2010, Use of sulphonylurea and cancer in type 2 diabetes—the Hong Kong Diabetes Registry, Diabetes Res Clin Pract, 90, 343, 10.1016/j.diabres.2010.08.022 Azoulay, 2011, Metformin and the incidence of prostate cancer in patients with type 2 diabetes, Cancer Epidemiol Biomarkers Prev, 20, 337, 10.1158/1055-9965.EPI-10-0940 Baur, 2011, Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort, Metabolism, 60, 1363, 10.1016/j.metabol.2010.09.012 Bodmer, 2011, Use of metformin and the risk of ovarian cancer: a case-control analysis, Gynecol Oncol, 123, 200, 10.1016/j.ygyno.2011.06.038 Bodmer, 2012, Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis, Am J Gastroenterol, 107, 620, 10.1038/ajg.2011.483 Bodmer, 2012, Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis, Cancer Epidemiol Biomarkers Prev, 21, 280, 10.1158/1055-9965.EPI-11-0992-T He, 2012, Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer, AnnOncol, 23, 1771 Villines, 2010, The ARBITER 6-HALTS Trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration, J Am Coll Cardiol, 55, 2721, 10.1016/j.jacc.2010.03.017 Bowker, 2010, Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure, Diabetologia, 53, 1631, 10.1007/s00125-010-1750-8 Axelson, 2007, Assessing dose-response relationships by cumulative exposure in epidemiological studies, Am J Ind Med, 50, 217, 10.1002/ajim.20377 Meira-Machado, 2009, Multi-state models for the analysis of time-to-event data, Stat Methods Med Res, 18, 195, 10.1177/0962280208092301 Bowker, 2011, Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women, Diabetes Care, 34, 2542, 10.2337/dc11-1199 Johnson, 2011, Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias, Diabetologia, 54, 2263, 10.1007/s00125-011-2242-1 Carstensen, 2012, Cancer occurrence in Danish diabetic patients: duration and insulin effects, Diabetologia, 55, 948, 10.1007/s00125-011-2381-4 Andersson, 2012, Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3·6 million people, BMJ Open, 2, e000433, 10.1136/bmjopen-2011-000433 Lewis, 2007, Medical therapy for diabetes is associated with increased use of lower endoscopy, Pharmacoepidemiol Drug Saf, 16, 1195, 10.1002/pds.1441 Mongan, 2012, Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a prospective observation study, Thromb Res, 129, 760, 10.1016/j.thromres.2011.12.019 Wood, 2004, The General Practice Research Database: role in pharmacovigilance, Drug Saf, 27, 871, 10.2165/00002018-200427120-00004 Dregan, 2012, Validity of cancer diagnosis in a primary care database compared with linked cancer registrations in England. Population-based cohort study, Cancer Epidemiol, 36, 425, 10.1016/j.canep.2012.05.013 Herrett, 2010, Validation and validity of diagnoses in the general practice research database: a systematic review, Br J Clin Pharmacol, 69, 4, 10.1111/j.1365-2125.2009.03537.x